Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Crown Bioscience Passes 1000 Model Mark in PDX Collection for Oncology Drug Discovery

Published: Wednesday, April 23, 2014
Last Updated: Tuesday, April 22, 2014
Bookmark and Share
Size of collection allows for more informed preclinical decision making on prospective drug candidates.

Crown Bioscience, Inc. has announced its HuPrime® PDX (Patient-Derived Xenograft) model collection has now passed the 1,000 individual models mark.

The HuPrime model collection, many of which are maintained ‘in life’, enable drug discovery companies to run Clinical Trial-like studies, or HuTrials™, using human surrogate models in mice. Such a comprehensive and diverse collection of well characterized models offers pharmaceutical and biotech partners a unique tool to improve the selection and development path for promising clinical candidates. This can significantly accelerate research programs, reducing the costs and failure rates of drug candidate development.

Patient-Derived Xenografts (PDX) involve extracting human tumors tissues directly from patients and transplanting them into surrogate immunodeficient mice. These models enable drug development and discovery companies to identify genetic signatures of disease, and discover and validate predictive biomarkers (HuSignature™) via performing human surrogate Phase II-like trials (HuTrials™).

Crown Bioscience has greatly expanded its capacity maintaining hundred of models live and running 10s of large-scale HuTrial™ efficacy studies in parallel, acquiring results in months, as opposed to years, and at a significantly lower cost compared to standard human clinical trials.

In addition to this unique Mouse Clinical Trial capacity, the accumulated HuTrial™ experience together with newly developed trial design and HuSignature™ algorithms, greatly enhances Crown’s ability to help partners obtain vital preclinical information essential to the success of their key clinical trials. By validating efficacy, studying and understanding mechanisms of action and resistance and identifying biomarkers, it is possible to improve the stratification of patient populations that may benefit from treatment regimens before entering the clinic.

Jean-Pierre Wery, President of Crown Bioscience, comments, “Passing the 1,000 model mark is a significant milestone in our mission to deliver the ‘gold standard’ in well-characterized models and services to help reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic. As drug discovery continues to rapidly evolve, there is a growing desire to screen candidates earlier with more patient-relevant disease models. We believe that through using models which more closely reflect the patient situation in the clinic, we can significantly accelerate our client’s research programs by helping them make better informed decisions about which compounds to progress into clinical trials.”

He continues, “Our comprehensive collection of models is continuing to rapidly expand and evolve, supported by our databases which enable our clients to rapidly identify models which best suit their needs. Screening candidates earlier with more patient-relevant disease models is helping improve the selection of candidates that are taken forward into the clinic. Earlier informed decision making and shorter trials are redefining the cost and success rate in drug development and discovery.”

Crown’s unique database of HuPrime models, HuBase™ offers a comprehensive database of genotypic, pharmacological, and clinical data, allowing clients to identify and choose the models that meet their criteria based on gene expression, RNAseq, copy number, response to Standard of Care, and many other criteria.

Crown Bioscience has a global footprint, spanning three major continents in North America, Europe, and Asia Pacific. The company offers a unique collection of ready-to-run, well-validated in vitro and in vivo models, model development expertise, comprehensive drug discovery platforms, and global capacity to help clients quantify the real efficacy and pharmacological profile of their candidates before they move into the clinic.

As the largest supplier of translational oncology services, Crown Bioscience is committed to providing its pharmaceutical and biopharmaceutical customers with specialized techniques and services to help the world-wide research community turn cancer from an incurable into a manageable, chronic disease and discover new targets and therapies in the treatment of metabolic diseases.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Novel Proteins Linked to Huntington's Disease
University of Florida Health researchers have made a new discovery about Huntington's disease, showing that the gene that causes the fatal disorder makes an unexpected "cocktail" of mutant proteins that accumulate in the brain.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
How Viruses Commandeer Human Proteins
Researchers have produced the first image of an important human protein as it binds with ribonucleic acid (RNA), a discovery that could offer clues to how some viruses, including HIV, control expression of their genetic material.
Tracking How Herpes Simplex Virus Moves Through Cells
In a recent study, Derek Walsh, PhD, associate professor of Microbiology-Immunology, and his team showed how the herpes simplex virus (HSV) exploits microtubule plus-end tracking proteins to initiate transport and infection in human cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos